S&P/TSX Composite Index Ends the Quarter 5.77% Higher at 22167.03, Record High Close Today — Data Talk
The S&P/TSX Composite Index is up 1208.59 points or 5.77% this quarter to 22167.03
--Up for two consecutive quarters
--Up 2625.76 points or 13.44% over the last two quarters
--Largest two-quarter point and percentage gain since the 2nd quarter 2021
--Up five of the past six quarters
--This month it is up 803.42 points or 3.76%
--Largest one-month point and percentage gain since Nov. 2023
--Up for five consecutive months
--Up 3293.56 points or 17.45% over the last five months
--Largest five-month percentage gain since March 2021
--Longest winning streak since Aug. 2021 when the market rose for seven straight months
--This week it is up 182.95 points or 0.83%
--Largest one-week point and percentage gain since the week ending March 8, 2024
--Up for seven consecutive weeks
--Up 1157.43 points or 5.51% over the last seven weeks
--Largest seven-week point and percentage gain since the week ending Dec. 29, 2023
--Longest winning streak since the week ending May 8, 2020 when the market rose for seven straight weeks
--Today it is up 59.95 points or 0.27%
--A new record close
--Up for two consecutive trading days
--Up 254.51 points or 1.16% over the last two trading days
--Largest two-day point and percentage gain since Thursday, March 7, 2024
--Up 18.30% from its 52-week low of 18737.39 hit Friday, Oct. 27, 2023
--Rose 11.16% from 52 weeks ago
--Up 7.69% from its 2024 closing low of 20584.97 hit Tuesday, Feb. 13, 2024
--Year-to-date it is up 1208.59 points or 5.77%
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 28, 2024 17:23 ET (21:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth